Company Profile
AIM Vaccine develops, manufactures, and sells vaccine products for human use in the People's Republic of China and globally. The company's product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia.
Its portfolio also includes iterative serum-free rabies vaccine, and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to treat COVID-19 infection Tetravalent meningococcal polysaccharide and conjugate vaccine, which is in phase II trials for the treatment of meningococcal disease; and EV71-CA16 Bivalent HFMD vaccine.
Additionally, it develops 20-valent and 24-valent pneumonia conjugate vaccine, haemophilus influenzae type b conjugate vaccine, absorbed tetanus vaccine, quadrivalent influenza virus vaccine (MDCK Cells), and human diploid rabies vaccine Hexavalent meningococcal vaccine to treat meningococcal disease.
Its portfolio also includes hexavalent group b streptococcus polysaccharide conjugate vaccine, mRNA human rabies vaccine, mRNA Shingles/Herpes Zoster vaccine, mRNA respiratory syncytial virus vaccine, diphtheria, tetanus, pertussis and haemophilus influenzae type b, and acellular pertussis combination vaccine for the treatment of DTP, and recombinant group B meningococcal vaccine to treat meningococcal disease.
Incorporated in 2011 and headquartered in Beijing, the People's Republic of China, the company was formerly known as Beijing AIM Biological Vaccine Technology Group Co., Ltd. before rebranding in September 2020.